Ferris L E, Basinski A S
CMAJ. 1996 Jan 15;154(2):185-7.
Dr. Ellen R. Wiebe's study of the use of methotrexate and misoprostol in combination for early termination of intrauterine pregnancy (see pages 165 to 170 of this issue) is the first Canadian study of the use of this drug combination for medical abortion. The authors compare Wiebe's findings with those of earlier studies on methotrexate and misoprostol, as well as with European findings on the use of mifepristone with prostaglandins. The authors argue that although the methotrexate-misoprostol combination appears to be reasonably safe for the woman, the failure rate and the teratogenicity of methotrexate and misoprosol give cause for concern. The authors conclude that medical abortions ought to be offered only where there is adequate access to laboratory and surgical facilities and where losses to follow-up are systematically minimized to reduce the potential for continued pregnancy resulting in congenital abnormality.
艾伦·R·维贝博士关于联合使用甲氨蝶呤和米索前列醇进行早期终止宫内妊娠的研究（见本期第165至170页）是加拿大第一项关于使用这种药物组合进行药物流产的研究。作者将维贝的研究结果与早期关于甲氨蝶呤和米索前列醇的研究结果以及欧洲关于米非司酮与前列腺素联合使用的研究结果进行了比较。作者认为，尽管甲氨蝶呤-米索前列醇组合对女性似乎相当安全，但甲氨蝶呤和米索前列醇的失败率和致畸性令人担忧。作者得出结论，只有在有足够的实验室和手术设施，且系统地将随访失访率降至最低以减少导致先天性异常的持续妊娠可能性的情况下，才应提供药物流产。
